Overview

ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)

Status:
Recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant brain tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells. ONC206 alone or in combination with radiation therapy may be effective in treating newly diagnosed or recurrent diffuse midline gliomas and other recurrent primary malignant brain tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Sabine Mueller, MD, PhD

Collaborators:

Chimerix
Mithil Prasad Foundation
Oncoceutics, Inc.
Storm the Heavens Fund
The ChadTough Defeat DIPG Foundation

Treatments:

Dopamine